Key result
TAVR in 2013-2015 linked to ~47% lower 30-day mortality versus 2010-2012 alongside increased device success.
Why the study?
National data regarding TAVR procedural characteristics and clinical outcomes over time were limited.
Does transcatheter aortic valve replacement (TAVR) show improved procedural and clinical outcomes over time in patients with severe aortic stenosis?
Cohort (n=16,969)
Yes
Does transcatheter aortic valve replacement (TAVR) show improved procedural and clinical outcomes over time in patients with severe aortic stenosis?
TAVR performance and short-term mortality improved significantly over a 6-year period in France, though rates of cardiac tamponade and pacemaker implantation increased.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“the two most widely used transcatheter heart valve designs may not achieve the same clinical outcomes. Overall, the present study strongly supports conducting a randomized trial in order to compare head-to-head the most recent iterations of self-expanding and balloon-expanding transcatheter heart valves on all-cause mortality.”
“perhaps there is an inherent difference between the TAVR valves. It may be incorrect to assume that there is a class effect.”
“a potential difference in mortality, but it's relatively small and it's not in a randomized trial. So I don't know that at this point this kind of data will switch people from self-expanding to balloon expandable devices alone, but one could consider it another factor.”
Provides real-world reassurance on the safety and procedural evolution of transcatheter aortic valve replacement; extends.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. OBJECTIVES: The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. METHODS: TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwards 2) registry, which captured all TAVRs performed from January 2010 to January 2012 across 34 centers. RESULTS: A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis. The median age of patients was 84.6 years, and 49.7% were men. FRANCE TAVI participants were older but at lower surgical risk (median logistic European System for Cardiac Operative Risk Evaluation [EuroSCORE]: 15.0% vs. 18.4%; p < 0.001). More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR. Transesophageal echocardiography guidance decreased from 60.7% to 32.3% of cases, whereas more recent procedures were increasingly performed in hybrid operating rooms (15.8% vs. 35.7%). Rates of Valve Academic Research Consortium-defined device success increased from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001). In-hospital and 30-day mortality rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRANCE 2 (p < 0.001 for both). Stroke and potentially life-threatening complications, such as annulus rupture or aortic dissection, remained stable over time, whereas rates of cardiac tamponade and pacemaker implantation significantly increased. CONCLUSIONS: The FRANCE TAVI registry provided reassuring data regarding trends in TAVR performance in an all-comers population on a national scale. Nonetheless, given that TAVR indications are likely to expand to patients at lower surgical risk, concerns remain regarding potentially life-threatening complications and pacemaker implantation. (Registry of Aortic Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).
No takes yet. Share an insight, caveat, or question.
Belle et al. (2017) conducted a cohort in Severe aortic stenosis (n=16,969). TAVR between 2013-2015 (FRANCE TAVI) vs. TAVR between 2010-2012 (FRANCE 2) was evaluated on 30-day mortality (p=<0.001). TAVR performed in France between 2013-2015 was associated with lower 30-day mortality compared to 2010-2012, alongside increased device success.
Synapse has enriched 10 related papers. Consider them for comparative context: